1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antidiabetic Biguanides Revenue
1.4 Market Analysis by Type
1.4.1 Global Antidiabetic Biguanides Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Metformin IR
1.4.3 Metformin SR
1.5 Market by Application
1.5.1 Global Antidiabetic Biguanides Market Share by Application: 2021-2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Antidiabetic Biguanides Market
1.8.1 Global Antidiabetic Biguanides Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Antidiabetic Biguanides Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Antidiabetic Biguanides Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Antidiabetic Biguanides Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Antidiabetic Biguanides Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Antidiabetic Biguanides Sales Volume Market Share by Region (2015-2020)
3.2 Global Antidiabetic Biguanides Sales Revenue Market Share by Region (2015-2020)
3.3 North America Antidiabetic Biguanides Sales Volume
3.3.1 North America Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.3.2 North America Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Antidiabetic Biguanides Sales Volume
3.4.1 East Asia Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Antidiabetic Biguanides Sales Volume (2015-2020)
3.5.1 Europe Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Antidiabetic Biguanides Sales Volume (2015-2020)
3.6.1 South Asia Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Antidiabetic Biguanides Sales Volume (2015-2020)
3.7.1 Southeast Asia Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Antidiabetic Biguanides Sales Volume (2015-2020)
3.8.1 Middle East Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Antidiabetic Biguanides Sales Volume (2015-2020)
3.9.1 Africa Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Antidiabetic Biguanides Sales Volume (2015-2020)
3.10.1 Oceania Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Antidiabetic Biguanides Sales Volume (2015-2020)
3.11.1 South America Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.11.2 South America Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Antidiabetic Biguanides Sales Volume (2015-2020)
3.12.1 Rest of the World Antidiabetic Biguanides Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Antidiabetic Biguanides Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Antidiabetic Biguanides Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Antidiabetic Biguanides Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Antidiabetic Biguanides Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Antidiabetic Biguanides Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Antidiabetic Biguanides Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Antidiabetic Biguanides Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Antidiabetic Biguanides Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Antidiabetic Biguanides Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Antidiabetic Biguanides Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Antidiabetic Biguanides Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Antidiabetic Biguanides Sales Volume Market Share by Type (2015-2020)
14.2 Global Antidiabetic Biguanides Sales Revenue Market Share by Type (2015-2020)
14.3 Global Antidiabetic Biguanides Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Antidiabetic Biguanides Consumption Volume by Application (2015-2020)
15.2 Global Antidiabetic Biguanides Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Antidiabetic Biguanides Business
16.1 Pfizer
16.1.1 Pfizer Company Profile
16.1.2 Pfizer Antidiabetic Biguanides Product Specification
16.1.3 Pfizer Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Novo Nordisk
16.2.1 Novo Nordisk Company Profile
16.2.2 Novo Nordisk Antidiabetic Biguanides Product Specification
16.2.3 Novo Nordisk Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Merck & Co
16.3.1 Merck & Co Company Profile
16.3.2 Merck & Co Antidiabetic Biguanides Product Specification
16.3.3 Merck & Co Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 AstraZeneca
16.4.1 AstraZeneca Company Profile
16.4.2 AstraZeneca Antidiabetic Biguanides Product Specification
16.4.3 AstraZeneca Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Takeda Pharmaceuticals
16.5.1 Takeda Pharmaceuticals Company Profile
16.5.2 Takeda Pharmaceuticals Antidiabetic Biguanides Product Specification
16.5.3 Takeda Pharmaceuticals Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 GlaxoSmithKline
16.6.1 GlaxoSmithKline Company Profile
16.6.2 GlaxoSmithKline Antidiabetic Biguanides Product Specification
16.6.3 GlaxoSmithKline Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Boehringer Ingelheim
16.7.1 Boehringer Ingelheim Company Profile
16.7.2 Boehringer Ingelheim Antidiabetic Biguanides Product Specification
16.7.3 Boehringer Ingelheim Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Sanofi
16.8.1 Sanofi Company Profile
16.8.2 Sanofi Antidiabetic Biguanides Product Specification
16.8.3 Sanofi Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Eli Lilly
16.9.1 Eli Lilly Company Profile
16.9.2 Eli Lilly Antidiabetic Biguanides Product Specification
16.9.3 Eli Lilly Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Servier Laboratories
16.10.1 Servier Laboratories Company Profile
16.10.2 Servier Laboratories Antidiabetic Biguanides Product Specification
16.10.3 Servier Laboratories Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Bristol-Myers Squibb
16.11.1 Bristol-Myers Squibb Company Profile
16.11.2 Bristol-Myers Squibb Antidiabetic Biguanides Product Specification
16.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Antidiabetic Biguanides Manufacturing Cost Analysis
17.1 Antidiabetic Biguanides Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Antidiabetic Biguanides
17.4 Antidiabetic Biguanides Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Antidiabetic Biguanides Distributors List
18.3 Antidiabetic Biguanides Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Antidiabetic Biguanides (2021-2026)
20.2 Global Forecasted Revenue of Antidiabetic Biguanides (2021-2026)
20.3 Global Forecasted Price of Antidiabetic Biguanides (2015-2026)
20.4 Global Forecasted Production of Antidiabetic Biguanides by Region (2021-2026)
20.4.1 North America Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.3 Europe Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.7 Africa Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.9 South America Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Antidiabetic Biguanides Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Antidiabetic Biguanides by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Antidiabetic Biguanides by Country
21.2 East Asia Market Forecasted Consumption of Antidiabetic Biguanides by Country
21.3 Europe Market Forecasted Consumption of Antidiabetic Biguanides by Countriy
21.4 South Asia Forecasted Consumption of Antidiabetic Biguanides by Country
21.5 Southeast Asia Forecasted Consumption of Antidiabetic Biguanides by Country
21.6 Middle East Forecasted Consumption of Antidiabetic Biguanides by Country
21.7 Africa Forecasted Consumption of Antidiabetic Biguanides by Country
21.8 Oceania Forecasted Consumption of Antidiabetic Biguanides by Country
21.9 South America Forecasted Consumption of Antidiabetic Biguanides by Country
21.10 Rest of the world Forecasted Consumption of Antidiabetic Biguanides by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer